Literature DB >> 1712245

Transduction and expression of the human carcinoembryonic antigen gene in a murine colon carcinoma cell line.

P F Robbins1, J A Kantor, M Salgaller, P H Hand, P D Fernsten, J Schlom.   

Abstract

A cell line derived from the mouse colon adenocarcinoma, MC-38, has been transduced with a retroviral construct containing complementary DNA encoding the human carcinoembryonic antigen (CEA) gene. MC-38, which forms tumors in syngeneic C57BL/6 mice, has been extensively studied as a target for active immunotherapy. Individual transduced clones that express high levels of cell surface CEA were isolated, and two clones, termed MC-38-ceal and MC-38-cea2, were extensively characterized. The levels of CEA found on the surface of these clones were considerably higher than that found in a moderately differentiated human colon carcinoma cell line (WiDr) and were comparable to those found on the human colon carcinoma cell lines GEO and CBS (among the highest CEA-expressing cells reported). Further analysis demonstrated that the CEA expressed in the MC-38-cea1 clone had a similar molecular weight to native CEA (Mr 180,000), but the MC-38-cea2 cell line expressed a single Mr 70,000 glycosylated immunoreactive product. Seven anti-CEA monoclonal antibodies were found to react with both clones. The CEA gene present in the MC-38-cea2 clone was partially sequenced and was found to contain a deletion of two of the three repeated domains present in CEA. These results provide a basis for future studies to map immunodominant epitopes of CEA and to develop a syngeneic model system that may aid in the design of reagents and protocols to study active and passive immunotherapy directed against a carcinoma expressing human CEA.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1712245

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  63 in total

1.  Consequence of dose scheduling of sunitinib on host immune response elements and vaccine combination therapy.

Authors:  Benedetto Farsaci; Jack P Higgins; James W Hodge
Journal:  Int J Cancer       Date:  2011-08-08       Impact factor: 7.396

2.  Abscopal regression of antigen disparate tumors by antigen cascade after systemic tumor vaccination in combination with local tumor radiation.

Authors:  James W Hodge; Hadley J Sharp; Sofia R Gameiro
Journal:  Cancer Biother Radiopharm       Date:  2012-01-27       Impact factor: 3.099

3.  Multiple costimulatory modalities enhance CTL avidity.

Authors:  James W Hodge; Mala Chakraborty; Chie Kudo-Saito; Charlie T Garnett; Jeffrey Schlom
Journal:  J Immunol       Date:  2005-05-15       Impact factor: 5.422

4.  4-1BB ligand enhances tumor-specific immunity of poxvirus vaccines.

Authors:  Chie Kudo-Saito; James W Hodge; Heesun Kwak; Seunghee Kim-Schulze; Jeffrey Schlom; Howard L Kaufman
Journal:  Vaccine       Date:  2006-03-31       Impact factor: 3.641

5.  Vaccination with a recombinant Saccharomyces cerevisiae expressing a tumor antigen breaks immune tolerance and elicits therapeutic antitumor responses.

Authors:  Elizabeth K Wansley; Mala Chakraborty; Kenneth W Hance; Michael B Bernstein; Amanda L Boehm; Zhimin Guo; Deborah Quick; Alex Franzusoff; John W Greiner; Jeffrey Schlom; James W Hodge
Journal:  Clin Cancer Res       Date:  2008-07-01       Impact factor: 12.531

6.  Tumor-induced impairment of TCR signaling results in compromised functionality of tumor-infiltrating regulatory T cells.

Authors:  M E Christine Lutsiak; Yutaka Tagaya; Anthony J Adams; Jeffrey Schlom; Helen Sabzevari
Journal:  J Immunol       Date:  2008-05-01       Impact factor: 5.422

7.  Oncolytic measles virus encoding interleukin-12 mediates potent antitumor effects through T cell activation.

Authors:  Rūta Veinalde; Christian Grossardt; Laura Hartmann; Marie-Claude Bourgeois-Daigneault; John C Bell; Dirk Jäger; Christof von Kalle; Guy Ungerechts; Christine E Engeland
Journal:  Oncoimmunology       Date:  2017-01-31       Impact factor: 8.110

8.  PD-1 blockade reverses adaptive immune resistance induced by high-dose hypofractionated but not low-dose daily fractionated radiation.

Authors:  Megan Morisada; Paul E Clavijo; Ellen Moore; Lillian Sun; Michael Chamberlin; Carter Van Waes; James W Hodge; James B Mitchell; Jay Friedman; Clint T Allen
Journal:  Oncoimmunology       Date:  2017-11-27       Impact factor: 8.110

9.  Induction of delayed-type hypersensitivity responses by monoclonal anti-idiotypic antibodies to tumor cells expressing carcinoembryonic antigen and tumor-associated glycoprotein-72.

Authors:  K Irvine; J Schlom
Journal:  Cancer Immunol Immunother       Date:  1993-05       Impact factor: 6.968

10.  Immune consequences of decreasing tumor vasculature with antiangiogenic tyrosine kinase inhibitors in combination with therapeutic vaccines.

Authors:  Benedetto Farsaci; Renee N Donahue; Michael A Coplin; Italia Grenga; Lauren M Lepone; Alfredo A Molinolo; James W Hodge
Journal:  Cancer Immunol Res       Date:  2014-08-04       Impact factor: 11.151

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.